SCHOTT Pharma KGaA (1SXP) Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 1SXP from our risk checks.
1SXP Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.70 |
| 52 Week High | €28.50 |
| 52 Week Low | €12.62 |
| Beta | 0.95 |
| 1 Month Change | 7.22% |
| 3 Month Change | 40.81% |
| 1 Year Change | -29.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.26% |
Recent News & Updates
Narrative Update • Jul 01
1SXP: Higher Discount Rate And Lower P/E Will Pressure Future Returns
Analysts have reduced their price target for SCHOTT Pharma KGaA from €14.00 to €13.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated new production lines for standard and sterile ready-to-use glass vials in Lebanon, Pennsylvania, aimed at a wide range of injectable drugs including biologics, vaccines, and emergency room medications.
Narrative Update • Jun 17
1SXP: Lebanon Capacity Expansion And 2026 Guidance Will Support Future Upside
Analysts have maintained their fair value estimate for SCHOTT Pharma KGaA at €19.43, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions leading to a marginally updated price target framework. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated expanded vial production lines in Lebanon, Pennsylvania, covering both standard and sterile ready to use glass vials for biologics, vaccines, complex injectable therapies and emergency room medications.Narrative Update • Jun 02
1SXP: Confirmed 2026 Guidance And Earnings Quality Will Support Future Upside
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly higher to about €19.43 from roughly €19.14, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News SCHOTT Pharma KGaA has confirmed its earnings guidance for the 2026 financial year.Analysis Article • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...Recent updates
Narrative Update • Jul 01
1SXP: Higher Discount Rate And Lower P/E Will Pressure Future Returns
Analysts have reduced their price target for SCHOTT Pharma KGaA from €14.00 to €13.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated new production lines for standard and sterile ready-to-use glass vials in Lebanon, Pennsylvania, aimed at a wide range of injectable drugs including biologics, vaccines, and emergency room medications.Narrative Update • Jun 17
1SXP: Lebanon Capacity Expansion And 2026 Guidance Will Support Future Upside
Analysts have maintained their fair value estimate for SCHOTT Pharma KGaA at €19.43, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions leading to a marginally updated price target framework. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated expanded vial production lines in Lebanon, Pennsylvania, covering both standard and sterile ready to use glass vials for biologics, vaccines, complex injectable therapies and emergency room medications.Narrative Update • Jun 02
1SXP: Confirmed 2026 Guidance And Earnings Quality Will Support Future Upside
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly higher to about €19.43 from roughly €19.14, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News SCHOTT Pharma KGaA has confirmed its earnings guidance for the 2026 financial year.Analysis Article • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...
Narrative Update • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.Narrative Update • Apr 29
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Narrative Update • Apr 14
1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).Narrative Update • Mar 31
1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).Narrative Update • Mar 17
1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.Narrative Update • Mar 03
1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Narrative Update • Feb 17
1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).Analysis Article • Feb 14
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) defied analyst predictions to release its first-quarter results, which were...Narrative Update • Feb 02
1SXP: Fair Outlook Will Balance Dividend Payout With Leadership Transition
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €14.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that they see as balancing out overall. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, payable on February 6, 2026, with an ex date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Analysis Article • Feb 02
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 18x, you may consider...Narrative Update • Jan 19
1SXP: Dividend Initiation Will Support Confidence In Revised Long Term Outlook
Analysts have reduced their price target for SCHOTT Pharma KGaA from €36.00 to €26.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which point to a more conservative outlook on the shares' fair value. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, an ex dividend date on February 4, 2026, and a record date on February 5, 2026 (Key Developments).Narrative Update • Jan 05
1SXP: Leadership Transition And Dividend Policy Will Support Future Profitability
Analysts have trimmed their fair value estimate for SCHOTT Pharma KGaA from €28.28 to €22.97, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple as key drivers of the change. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, ex-date on February 4, 2026, and record date on February 5, 2026 (Key Developments).Narrative Update • Dec 20
1SXP Outlook Will Balance Lower Expectations With Dividend And Leadership Transition
Analysts have reduced their price target on SCHOTT Pharma KGaA from €22.00 to €14.00, reflecting tempered expectations for revenue growth, profit margins, and future valuation multiples in an environment characterized by higher discount rates. What's in the News SCHOTT Pharma AG & Co. KGaA declared an annual dividend of EUR 0.18 per share, payable on February 6, 2026, with an ex-dividend date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Analysis Article • Dec 15
SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) has announced that it will be increasing its periodic dividend on the 6th of...Narrative Update • Dec 06
1SXP: Leadership Transition Will Support Future Profitability And Operational Discipline
Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.Analysis Article • Nov 24
A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights SCHOTT Pharma KGaA's estimated fair value is €21.30 based on 2 Stage Free Cash Flow to Equity With €18.44...Narrative Update • Nov 22
1SXP: Leadership Transition Will Drive Renewed Operational Focus And Profitability
Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models. What's in the News Christian Mias appointed as CEO of SCHOTT Pharma KGaA.Analysis Article • Nov 02
Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Sep 19
Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analysis Article • Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its quarterly result to the...Analysis Article • Jul 19
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jun 13
Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) came out with its second-quarter results last week, and we wanted to see how...Analysis Article • Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Key Insights SCHOTT Pharma KGaA's estimated fair value is €39.60 based on 2 Stage Free Cash Flow to Equity SCHOTT...Analysis Article • Mar 22
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 12
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analysis Article • Jan 13
Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €49.59 based on 2 Stage Free Cash Flow to Equity SCHOTT...
New Narrative • Dec 16
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.Analysis Article • Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
SCHOTT Pharma AG & Co. KGaA's ( ETR:1SXP ) price-to-earnings (or "P/E") ratio of 31.5x might make it look like a strong...Analysis Article • Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) investors will be delighted, with the company turning in some strong numbers...Analysis Article • Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €47.81 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
It's been a pretty great week for SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) shareholders, with its shares surging 11% to...Analysis Article • Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights The projected fair value for SCHOTT Pharma KGaA is €34.80 based on 2 Stage Free Cash Flow to Equity SCHOTT...Shareholder Returns
| 1SXP | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 9.0% | 1.3% | 4.1% |
| 1Y | -29.3% | -9.4% | 2.9% |
Return vs Industry: 1SXP underperformed the German Life Sciences industry which returned -9.4% over the past year.
Return vs Market: 1SXP underperformed the German Market which returned 2.9% over the past year.
Price Volatility
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1SXP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1SXP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,839 | Christian Mias | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXP fundamental statistics | |
|---|---|
| Market cap | €2.63b |
| Earnings (TTM) | €142.82m |
| Revenue (TTM) | €991.22m |
19.7x
P/E Ratio2.8x
P/S RatioIs 1SXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXP income statement (TTM) | |
|---|---|
| Revenue | €991.22m |
| Cost of Revenue | €664.75m |
| Gross Profit | €326.47m |
| Other Expenses | €183.65m |
| Earnings | €142.82m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 12, 2026
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 32.94% |
| Net Profit Margin | 14.41% |
| Debt/Equity Ratio | 23.7% |
How did 1SXP perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 18:02 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |